New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
07:03 EDTAMRNAmarin announces Vascepa case study publication
Amarin announced the publication of a retrospective analysis of patient cases that examined the effect on lipid parameters in hyperlipidemic patients who were switched from Lovaza capsules to Vascepa capsules. During the studied period, most of the 14 patients switched to Vascepa experienced reductions in levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. The company said, "We have heard many anecdotal reports of the success physicians have had with Vascepa since its launch last year. The results published by Dr. Castaldo provide important hypothesis generating evidence of the potential benefit of treating patients with EPA-only Vascepa that requires additional study for substantiation. These real-world results are exciting and encouraging when considered alongside the findings of the pivotal Phase 3 studies conducted with Vascepa, which demonstrated that EPA-only Vascepa reduced TG levels without increasing levels of bad cholesterol, LDL-C, in patients with high and very high triglyceride levels."
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:17 EDTAMRNAmarin announces two presentations on EPA dyslipidemia studies
Amarin announced the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only Vascepa as well as a sub-analysis of the ANCHOR clinical trial, at two key cardiovascular meetings. The EPA+DHA to EPA-only switch study investigated the effect of EPA-only omega-3 therapy compared to EPA+DHA therapy on multiple patient lipid parameters. Results of this case series showed a reduction in both triglyceride and low-density lipoprotein cholesterol levels with EPA-only therapy in most of these high-risk statin-treated patients. The ANCHOR sub-analysis is an encore presentation which examined the effect of EPA on high-risk statin-treated patients with persistently high triglyceride levels, showing that icosapent ethyl increased EPA in plasma and red blood cells in a linear, dose-dependent fashion consistent with its triglyceride-lowering effect.
July 24, 2015
16:38 EDTAMRNAmarin files to sell 38.9M series A preference shares in form of ADS for holders
Subscribe for More Information
16:34 EDTAMRNAmarin files to sell 3.89M ordinary shares in form of ADS for holders
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use